当前位置： SCI文献检索 > HIV MEDICINE期刊下所有文献 > Financial stress is associated with reduced treatment adherence in HIV-infected adults in a resource-rich setting.

Financial stress is associated with reduced treatment adherence in HIV-infected adults in a resource-rich setting.

Abstract：

OBJECTIVES:Financial stress has been identified as a barrier to antiretroviral adherence, but only in resource- limited settings. Almost half of HIV-infected Australian adults earn no regular income and, despite highly subsidised antiretroviral therapy and universal health care, 3% of HIV-infected Australians cease antiretroviral therapy each year. We studied the relationship between financial stress and treatment adherence in a resource-rich setting. METHODS:Out-patients attending the HIV clinic at St Vincent's Hospital between November 2010 and May 2011 were invited to complete an anonymous survey including questions relating to costs and adherence. RESULTS:Of 335 HIV-infected patients (95.8% male; mean age 52 years; hepatitis coinfection 9.2%), 65 patients (19.6%) stated that it was difficult or very difficult to meet pharmacy dispensing costs, 49 (14.6%) reported that they had delayed purchasing medication because of pharmacy costs, and 30 (9.0%) reported that they had ceased medication because of pharmacy costs. Of the 65 patients with difficulties meeting pharmacy costs, 19 (29.2%) had ceased medication vs. 11 (4.1%) of the remaining 270 patients (P < 0.0001). In addition, 19 patients (5.7%) also stated that it was difficult or very difficult to meet travel costs to the clinic. Treatment cessation and interruption were both independently associated with difficulty meeting both pharmacy and clinic travel costs. Only 4.9% had been asked if they were having difficulty paying for medication. CONCLUSIONS:These are the first data to show that pharmacy dispensing and clinic travel costs may affect treatment adherence in a resource-rich setting. Patients should be asked if financial stress is limiting their treatment adherence.

journal_name

HIV Med

journal_title

HIV medicine

authors

McAllister J,Beardsworth G,Lavie E,MacRae K,Carr A

doi

10.1111/j.1468-1293.2012.01034.x

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

120-4

issue

2

eissn

1464-2662

issn

1468-1293

journal_volume

14

pub_type

杂志文章

相关文献

HIV MEDICINE文献大全
  • The case for indicator condition-guided HIV screening.

    abstract：:One-half of the estimated 2.5 million people who now live with HIV in the World Health Organization (WHO) European Region are still diagnosed late. A central question is which clinical scenarios should trigger an HIV test recommendation in order to avoid late presentation. Drawing on the work of the HIV Indicator Dise...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12022

    authors： Lazarus JV,Hoekstra M,Raben D,Delpech V,Coenen T,Lundgren JD,HIV in Europe Initiative Steering Committee.

    更新日期：2013-08-01 00:00:00

  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract：OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12831

    authors： Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期：2020-07-01 00:00:00

  • Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

    abstract：BACKGROUND:More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS:In 2005, 34 departments prospectively recorded all dea...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1468-1293.2008.00686.x

    authors： Rosenthal E,Salmon-Céron D,Lewden C,Bouteloup V,Pialoux G,Bonnet F,Karmochkine M,May T,François M,Burty C,Jougla E,Costagliola D,Morlat P,Chêne G,Cacoub P,Mortavic\/Mortalité 2005 Study Group.

    更新日期：2009-05-01 00:00:00

  • Frequency of HIV testing among gay and bisexual men in the UK: implications for HIV prevention.

    abstract：OBJECTIVES:The aim of the study was to explore HIV testing frequency among UK men who have sex with men (MSM) in order to direct intervention development. METHODS:Cross-sectional surveys were completed by 2409 MSM in Edinburgh, Glasgow and London in 2011 and a Scotland-wide online survey was carried out in 2012/13. Th...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12373

    authors： McDaid LM,Aghaizu A,Frankis J,Riddell J,Nardone A,Mercey D,Johnson AM,Hart GJ,Flowers P

    更新日期：2016-10-01 00:00:00

  • Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.

    abstract：OBJECTIVES:Although current guidelines recommend resistance testing prior to antiretroviral therapy (ART) reinitiation after treatment interruptions, virological failure of first-line ritonavir-boosted, protease-inhibitor (PI/r)-containing ART is associated with low emergent PI resistance. In patients experiencing unsc...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12107

    authors： Tinago W,O'Halloran JA,O'Halloran RM,Macken A,Lambert JS,Sheehan GJ,Mallon PW

    更新日期：2014-04-01 00:00:00

  • Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.

    abstract：OBJECTIVES:Different experimental approaches have shown that, despite plasma viral loads under the threshold of detection, HIV-1 frequently continues to replicate in patients receiving potent antiretroviral therapy. However, whether this low-grade viral replication is sufficient for the generation of new major quasispe...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1046/j.1468-1293.2000.00030.x

    authors： Birk M,Aleman S,Visco-Comandini U,Sönnerborg A

    更新日期：2000-10-01 00:00:00

  • Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

    abstract：OBJECTIVES:Efforts are needed to improve informed consent of participants in research. The Strategic Timing of AntiRetroviral Therapy (START) study provides a unique opportunity to study the effect of length and complexity of informed consent documents on understanding and satisfaction among geographically diverse part...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/hiv.12230

    authors： Denning E,Sharma S,Smolskis M,Touloumi G,Walker S,Babiker A,Clewett M,Emanuel E,Florence E,Papadopoulos A,Sánchez A,Tavel J,Grady C,International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Grou

    更新日期：2015-04-01 00:00:00

  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract：:Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title：HIV medicine

    pub_type： 杂志文章,评审

    doi：10.1046/j.1468-1293.2000.00027.x

    authors： Hermans P

    更新日期：2000-07-01 00:00:00

  • Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

    abstract：BACKGROUND:Tuberculosis (TB) is a common opportunistic infection among HIV-infected people, and rifampicin is an important drug for the treatment of TB. However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions. ME...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2007.00442.x

    authors： Mallolas J,Sarasa M,Nomdedeu M,Soriano A,López-Púa Y,Blanco JL,Martínez E,Gatell JM

    更新日期：2007-03-01 00:00:00

  • Correlating HIV tropism with immunological response under combination antiretroviral therapy.

    abstract：OBJECTIVES:A significant percentage of patients infected with HIV-1 experience only suboptimal CD4 cell recovery while treated with combination therapy (cART). It is still unclear whether viral properties such as cell tropism play a major role in this incomplete immune response. This study therefore intended to follow ...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12365

    authors： Bader J,Schöni-Affolter F,Böni J,Gorgievski-Hrisoho M,Martinetti G,Battegay M,Klimkait T,Swiss HIV Cohort Study.

    更新日期：2016-09-01 00:00:00

  • Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults.

    abstract：OBJECTIVES:The acquisition of adequate vaccine-induced humoral immunity is especially important in HIV-infected individuals, who are at increased risk of infections. The aim of the study was to assess the safety of administering a complete vaccination programme to successfully treated HIV-infected adults and to evaluat...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1468-1293.2010.00830.x

    authors： González R,Castro P,García F,Plana M,Bayas JM,Lafuente S,Serrano B,Mora B,Argelich R,Gatell JM,Vilella A

    更新日期：2010-09-01 00:00:00

  • Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.

    abstract：BACKGROUND:AIDS-related lymphoma (ARL) remains the main cause of AIDS-related deaths in the combined antiretroviral therapy (cART) era. Although most ARLs are associated with the Epstein-Barr virus (EBV), whether patients with high EBV burden are more at risk of developing ARL is unknown. This study investigated the re...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2012.00998.x

    authors： Leruez-Ville M,Seng R,Morand P,Boufassa F,Boue F,Deveau C,Rouzioux C,Goujard C,Seigneurin JM,Meyer L

    更新日期：2012-09-01 00:00:00

  • Euthanasia: from the perspective of HIV infected persons in Europe.

    abstract：BACKGROUND:In the debate about legalization of euthanasia very little attention has so far been given to the opinion of the patient. OBJECTIVE:To assess the opinion of persons with HIV infection in Europe. METHODS:A cross-sectional survey of persons with HIV infection attending HIV/AIDS treatment centres or HIV suppo...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1046/j.1468-1293.2001.00053.x

    authors： Andraghetti R,Foran S,Colebunders R,Tomlinson D,Vyras P,Borleffs CJ,Fleerackers Y,Schrooten W,Borchert M

    更新日期：2001-01-01 00:00:00

  • A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

    abstract：OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized...

    journal_title：HIV medicine

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1468-1293.2004.00224.x

    authors： Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

    更新日期：2004-07-01 00:00:00

  • The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

    abstract：OBJECTIVE:This study was designed to evaluate the effects of the HIV protease inhibitor lopinavir/ritonavir on gingival epithelium growth, integrity and differentiation. METHODS:Organotypic (raft) cultures of gingival keratinocytes were established and treated with a range of lopinavir/ritonavir concentrations. To exa...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2010.00863.x

    authors： Israr M,Mitchell D,Alam S,Dinello D,Kishel JJ,Meyers C

    更新日期：2011-03-01 00:00:00

  • Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

    abstract：OBJECTIVES:The aim of the study was to describe the prevalence and correlates of chronic obstructive pulmonary disease (COPD) in a multicentre international cohort of persons living with HIV (PLWH). METHODS:We performed a cross-sectional analysis of adult PLWH, naïve to HIV treatment, with baseline CD4 cell count > 50...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/hiv.12240

    authors： Kunisaki KM,Niewoehner DE,Collins G,Nixon DE,Tedaldi E,Akolo C,Kityo C,Klinker H,La Rosa A,Connett JE,International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

    更新日期：2015-04-01 00:00:00

  • Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.

    abstract：OBJECTIVES:The aim of the study was to identify differences in infant outcomes, virological efficacy, and preterm delivery (PTD) outcome between women exposed to lopinavir/ritonavir (LPV/r) and those exposed to atazanavir/ritonavir (ATV/r). METHODS:A retrospective case note review was carried out. The case notes of 49...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12277

    authors： Perry ME,Taylor GP,Sabin CA,Conway K,Flanagan S,Dwyer E,Stevenson J,Mulka L,McKendry A,Williams E,Barbour A,Dermont S,Roedling S,Shah R,Anderson J,Rodgers M,Wood C,Sarner L,Hay P,Hawkins D,deRuiter A

    更新日期：2016-01-01 00:00:00

  • Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

    abstract：OBJECTIVES:The aim of the study was to describe growth and body composition changes in HIV-positive children after they had initiated or changed antiretroviral therapy (ART) and to correlate these with viral, immune and treatment parameters. METHODS:Ninety-seven prepubertal HIV-positive children were observed over 48 ...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1468-1293.2010.00823.x

    authors： Chantry CJ,Cervia JS,Hughes MD,Alvero C,Hodge J,Borum P,Moye J Jr,PACTG 1010 Team.

    更新日期：2010-10-01 00:00:00

  • Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.

    abstract：OBJECTIVE:To study the impact of effective highly active antiretroviral therapy (HAART) on the preservation of long-term CD4 memory cells induced by vaccines in HIV-1-infected patients. METHODS:Thirty HIV-1-positive patients on HAART with undetectable viral load were randomized into three groups: 10 received HIV-1 rgp...

    journal_title：HIV medicine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1468-1293.2003.00148.x

    authors： Hejdeman B,Leandersson AC,Fredriksson EL,Sandström E,Wahren B,Bratt G

    更新日期：2003-04-01 00:00:00

  • Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

    abstract：BACKGROUND:The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy wit...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1468-1293.2009.00752.x

    authors： Ghosn J,Flandre P,Cohen-Codar I,Girard PM,Chaix ML,Raffi F,Dellamonica P,Ngovan P,Norton M,Delfraissy JF,MONARK Study Group.

    更新日期：2010-02-01 00:00:00

  • A global survey of HIV-positive people's attitudes towards cure research.

    abstract：OBJECTIVES:Involvement of people living with HIV (PLHIV) in the design of HIV cure studies is important, given the potential risks to participants. We present results of an international survey of PLHIV to define these issues and inform cure research. METHODS:PLHIV were recruited in June-November 2014 through HIV webs...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12391

    authors： Simmons R,Kall M,Collins S,Cairns G,Taylor S,Nelson M,Fidler S,Porter K,Fox J,Collaborative HIV Eradication of viral Reservoirs (CHERUB) Survey collaboration.

    更新日期：2017-02-01 00:00:00

  • Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

    abstract：OBJECTIVE:The aim of the study was to evaluate the predictive value of clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), for the development of lactic acidosis (LA) and symptomatic hyperlactataemia (SHL). METHODS:In a substu...

    journal_title：HIV medicine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1468-1293.2011.00934.x

    authors： Feeney ER,Chazallon C,O'Brien N,Meiffrédy V,Goodall RL,Aboulker JP,Cooper DA,Yeni P,Mallon PW,INITIO Trial International Co-ordinating Committee.

    更新日期：2011-11-01 00:00:00

  • Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

    abstract：BACKGROUND:ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized background regimen [OBR; at least two nucleoside reverse transc...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/hiv.12024

    authors： Sension M,Cahn P,Domingo P,Hodder S,Opsomer M,Lathouwers E,Van de Casteele T,Tomaka F

    更新日期：2013-08-01 00:00:00

  • Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

    abstract：OBJECTIVE:Study 903 was a 144-week, randomized, double-blind, active-controlled study of tenofovir disoproxil fumarate (TDF) therapy in treatment-naive HIV-1-infected patients. Patients received either TDF (n = 299) or stavudine (d4T) (n = 301) with lamivudine (3TC) and efavirenz (EFV). Resistance analyses were perform...

    journal_title：HIV medicine

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1468-1293.2006.00404.x

    authors： Margot NA,Lu B,Cheng A,Miller MD,Study 903 Team.

    更新日期：2006-10-01 00:00:00

  • How reliable is an undetectable viral load?

    abstract：OBJECTIVES:An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questio...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2009.00714.x

    authors： Combescure C,Vallier N,Ledergerber B,Cavassini M,Furrer H,Rauch A,Battegay M,Bernasconi E,Vernazza P,Hirschel B,Swiss HIV Cohort Study.

    更新日期：2009-09-01 00:00:00

  • Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

    abstract：OBJECTIVES:Pregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/rit...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12164

    authors： Else LJ,Jackson V,Brennan M,Back DJ,Khoo SH,Coulter-Smith S,Lambert JS

    更新日期：2014-11-01 00:00:00

  • Safe travels? HIV transmission among Britons travelling abroad.

    abstract：OBJECTIVES:The aim of the study was to identify and describe the characteristics of persons born in the UK who acquire HIV infection abroad. METHODS:Analyses using case reports and follow-up data from the national HIV database held at the Health Protection Agency were performed. RESULTS:Fifteen per cent (2066 of 13 8...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2011.00983.x

    authors： Rice B,Gilbart VL,Lawrence J,Smith R,Kall M,Delpech V

    更新日期：2012-05-01 00:00:00

  • HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.

    abstract：:The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a "new" chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors su...

    journal_title：HIV medicine

    pub_type： 杂志文章,评审

    doi：10.1111/hiv.12346

    authors： Lambert CT,Sandesara PB,Hirsh B,Shaw LJ,Lewis W,Quyyumi AA,Schinazi RF,Post WS,Sperling L

    更新日期：2016-06-01 00:00:00

  • Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy.

    abstract：BACKGROUND:Highly active antiretroviral therapy (HAART) has increased longevity. Currently, women comprise >50% of HIV-infected individuals worldwide. It is not known if there are differences between the sexes in the immunological and virological responses to HAART across the age strata. METHODS:Immunological reconsti...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/j.1468-1293.2007.00485.x

    authors： Patterson K,Napravnik S,Eron J,Keruly J,Moore R

    更新日期：2007-09-01 00:00:00

  • Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.

    abstract：OBJECTIVES:We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. METHODS:Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 inf...

    journal_title：HIV medicine

    pub_type： 杂志文章

    doi：10.1111/hiv.12611

    authors： Borghetti A,Baldin G,Lombardi F,Ciccullo A,Capetti A,Rusconi S,Sterrantino G,Latini A,Cossu MV,Gagliardini R,De Luca A,Di Giambenedetto S

    更新日期：2018-03-24 00:00:00